174 related articles for article (PubMed ID: 35377770)
21. What is new in multiple sclerosis spasticity research? Poster session highlights.
Ghezzi A
Neurodegener Dis Manag; 2016 Dec; 6(6s):45-47. PubMed ID: 27874498
[TBL] [Abstract][Full Text] [Related]
22. Long-term assessment of the cognitive effects of nabiximols in patients with multiple sclerosis: A pilot study.
Alessandria G; Meli R; Infante MT; Vestito L; Capello E; Bandini F
Clin Neurol Neurosurg; 2020 Sep; 196():105990. PubMed ID: 32526487
[TBL] [Abstract][Full Text] [Related]
23. Usability of an application device for nabiximols oromucosal spray in patients with upper limb impaired multiple sclerosis.
Creta A; Gilio L; Centonze D; Fantozzi R
Neurodegener Dis Manag; 2022 Aug; 12(4):195-201. PubMed ID: 35707977
[TBL] [Abstract][Full Text] [Related]
24. Safety and tolerability of nabiximols oromucosal spray: a review of more than 15 years" accumulated evidence from clinical trials.
Prieto González JM; Vila Silván C
Expert Rev Neurother; 2021 Jul; 21(7):755-778. PubMed ID: 34092180
[No Abstract] [Full Text] [Related]
25. The use of medical-grade cannabis in patients non-responders to Nabiximols.
Saccà F; Pane C; Carotenuto A; Massarelli M; Lanzillo R; Florio EB; Brescia Morra V
J Neurol Sci; 2016 Sep; 368():349-51. PubMed ID: 27538663
[No Abstract] [Full Text] [Related]
26. Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity.
Koehler J; Feneberg W; Meier M; Pöllmann W
Int J Neurosci; 2014 Sep; 124(9):652-6. PubMed ID: 24392812
[TBL] [Abstract][Full Text] [Related]
27. Effects of Sativex
Dykukha I; Essner U; Schreiber H; Raithel LM; Penner IK
Mult Scler Relat Disord; 2022 Dec; 68():104173. PubMed ID: 36174323
[TBL] [Abstract][Full Text] [Related]
28. A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis.
Arroyo González R
Expert Rev Neurother; 2018 Oct; 18(10):785-791. PubMed ID: 30235965
[TBL] [Abstract][Full Text] [Related]
29. Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study.
Patti F; Chisari CG; Solaro C; Benedetti MD; Berra E; Bianco A; Bruno Bossio R; Buttari F; Castelli L; Cavalla P; Cerqua R; Costantino G; Gasperini C; Guareschi A; Ippolito D; Lanzillo R; Maniscalco GT; Matta M; Paolicelli D; Petrucci L; Pontecorvo S; Righini I; Russo M; Saccà F; Salamone G; Signoriello E; Spinicci G; Spitaleri D; Tavazzi E; Trotta M; Zaffaroni M; Zappia M;
Neurol Sci; 2020 Oct; 41(10):2905-2913. PubMed ID: 32335779
[TBL] [Abstract][Full Text] [Related]
30. Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis.
Podda G; Constantinescu CS
Expert Opin Biol Ther; 2012 Nov; 12(11):1517-31. PubMed ID: 22954177
[TBL] [Abstract][Full Text] [Related]
31. Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice.
Flachenecker P; Henze T; Zettl UK
Eur Neurol; 2014; 72(1-2):95-102. PubMed ID: 24943098
[TBL] [Abstract][Full Text] [Related]
32. Nabiximols and botulinum toxin injections for patients with multiple sclerosis: efficacy on spasticity and spasms in a single-centre experience.
Sartori A; Dinoto A; Stragapede L; Mazzon G; Morelli ME; Pasquin F; Bratina A; Bosco A; Manganotti P
Neurol Sci; 2021 Dec; 42(12):5037-5043. PubMed ID: 33742336
[TBL] [Abstract][Full Text] [Related]
33. Resting-state functional connectivity in multiple sclerosis patients receiving nabiximols for spasticity.
Gajofatto A; Cardobi N; Gobbin F; Calabrese M; Turatti M; Benedetti MD
BMC Neurol; 2023 Mar; 23(1):128. PubMed ID: 36991352
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of nabiximols cannabinoid medicine for paediatric spasticity in cerebral palsy or traumatic brain injury: a randomized controlled trial.
Fairhurst C; Kumar R; Checketts D; Tayo B; Turner S
Dev Med Child Neurol; 2020 Sep; 62(9):1031-1039. PubMed ID: 32342496
[TBL] [Abstract][Full Text] [Related]
35. Evolution of multiple sclerosis spasticity-associated symptoms: latest data.
Flachenecker P
Neurodegener Dis Manag; 2016 Dec; 6(6s):9-12. PubMed ID: 27874495
[TBL] [Abstract][Full Text] [Related]
36. Health Authorities Data Collection of THC:CBD Oromucosal Spray (L'Agenzia Italiana del Farmaco Web Registry): Figures after 1.5 Years.
Patti F
Eur Neurol; 2016; 75 Suppl 1():9-12. PubMed ID: 26901344
[TBL] [Abstract][Full Text] [Related]
37. Nabiximols is Efficient as Add-On Treatment for Patients with Multiple Sclerosis Spasticity Refractory to Standard Treatment: A Systematic Review and Meta-Analysis of Randomised Clinical Trials.
Kleiner D; Horváth IL; Bunduc S; Gergő D; Lugosi K; Fehérvári P; Hegyi P; Csupor D
Curr Neuropharmacol; 2023; 21(12):2505-2515. PubMed ID: 37519000
[TBL] [Abstract][Full Text] [Related]
38. Palatability and oral cavity tolerability of THC:CBD oromucosal spray and possible improvement measures in multiple sclerosis patients with resistant spasticity: a pilot study.
Lus G; Cantello R; Danni MC; Rini A; Sarchielli P; Tassinari T; Signoriello E
Neurodegener Dis Manag; 2018 Apr; 8(2):105-113. PubMed ID: 29683408
[TBL] [Abstract][Full Text] [Related]
39. Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.
Vermersch P; Trojano M
Eur Neurol; 2016; 76(5-6):216-226. PubMed ID: 27732980
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity.
Patti F; Messina S; Solaro C; Amato MP; Bergamaschi R; Bonavita S; Bruno Bossio R; Brescia Morra V; Costantino GF; Cavalla P; Centonze D; Comi G; Cottone S; Danni M; Francia A; Gajofatto A; Gasperini C; Ghezzi A; Iudice A; Lus G; Maniscalco GT; Marrosu MG; Matta M; Mirabella M; Montanari E; Pozzilli C; Rovaris M; Sessa E; Spitaleri D; Trojano M; Valentino P; Zappia M;
J Neurol Neurosurg Psychiatry; 2016 Sep; 87(9):944-51. PubMed ID: 27160523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
